00:19 , Jul 30, 2019 |  BC Extra  |  Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

Despite multibillion dollar impairment, Sanofi beats on 2Q19 earnings  Sanofi (Euronext:SAN; NASDAQ:SNY) reported 2Q19 sales of €496 million from dermatitis and asthma drug Dupixent dupilumab, beating the Street's estimate of €411 million. The pharma also...
22:00 , Jul 3, 2019 |  BC Extra  |  Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
21:16 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting GM-CSF in CAR Ts to prevent therapy-induced cytokine release syndrome

DISEASE CATEGORY: Inflammation INDICATION: Cytokine release syndrome (CRS) Cell culture studies suggest inhibiting GM-CSF produced by CAR T cells could help prevent CRS in lymphoma patients receiving CAR T therapies. In a co-culture assay in...
13:02 , Feb 28, 2019 |  BC Extra  |  Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

Two studies have identified genes that could be knocked out from CAR T cells to improve efficacy or safety. While CAR T cells are effective against B cell malignancies, their efficacy in solid tumors has...
00:05 , Dec 12, 2018 |  BC Extra  |  Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

Merck & Co. Inc. (NYSE:MRK) said President of Global Human Health Adam Schechter will step down at the end of the year. The company will restructure his former position into two new roles effective Jan....
19:20 , Nov 19, 2018 |  BC Extra  |  Financial News

NASH company Genfit planning U.S. listing

As it prepares for a readout from a Phase III study of its lead candidate to treat non-alcoholic steatohepatitis, French bellwether Genfit S.A. (Euronext:GNFT) intends to conduct a listing on a U.S. exchange. Genfit said...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
18:04 , Oct 12, 2018 |  BC Week In Review  |  Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Oct. 10 in the largest IPO by a biotech on NASDAQ thus far in 2018. The...